Phase 1 Safety and PK Study of OLT1177 Capsules

Sponsor

Olatec Therapeutics LLC (Industry)

Overall Status

Completed

CT.gov ID

NCT02134964

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

5.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers after administration of single or multiple dose(s) of investigational drug (OLT1177 Caps or Placebo Caps). A total of 36 subjects will be enrolled across 6 cohorts, and subjects in each cohort will be randomized in a ratio of 5 active to 1 placebo.

Condition or Disease	Intervention/Treatment	Phase
Healthy Volunteers	Drug: OLT1177 Capsules Drug: Placebo Capsules	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

35 participants

Allocation:

Randomized

Intervention Model:

Single Group Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Basic Science

Official Title:

A Phase 1, Randomized, Dose Escalation, Single Center, Safety and Pharmacokinetic Study of Single and Multi-Dose, Orally Administered OLT1177 Capsules in Healthy Subjects

Study Start Date :

Jun 1, 2014

Actual Primary Completion Date :

Dec 1, 2014

Actual Study Completion Date :

Dec 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: OLT1177 Capsules A total of 5 patients in each cohort will receive OLT1177 Capsules: Cohort 1 will receive a single 100 mg dose of OLT1177 Cohort 2 will receive a single 300 mg dose of OLT1177 Cohort 3 will receive two 1000 mg doses of OLT1177 (seven days apart) Cohort 4 will receive 100 mg doses of OLT1177 QD for 8 days Cohort 5 will receive 300 mg doses of OLT1177 QD for 8 days Cohort 6 will receive 1000 mg doses of OLT1177 QD for 8 days	Drug: OLT1177 Capsules OLT1177 Capsules are an experimental drug.
Placebo Comparator: Placebo Capsules A total of 1 patient in each cohort will receive Placebo Capsules: Cohort 1 will receive a single placebo capsule Cohort 2 will receive three placebo capsules Cohort 3 will receive ten placebo capsules (seven days apart) Cohort 4 will receive a single placebo capsule QD for 8 days Cohort 5 will receive three placebo capsules QD for 8 days Cohort 6 will receive ten placebo capsules QD for 8 days	Drug: Placebo Capsules Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.

Arm

Intervention/Treatment

Experimental: OLT1177 Capsules

A total of 5 patients in each cohort will receive OLT1177 Capsules: Cohort 1 will receive a single 100 mg dose of OLT1177 Cohort 2 will receive a single 300 mg dose of OLT1177 Cohort 3 will receive two 1000 mg doses of OLT1177 (seven days apart) Cohort 4 will receive 100 mg doses of OLT1177 QD for 8 days Cohort 5 will receive 300 mg doses of OLT1177 QD for 8 days Cohort 6 will receive 1000 mg doses of OLT1177 QD for 8 days

Drug: OLT1177 Capsules

OLT1177 Capsules are an experimental drug.

Placebo Comparator: Placebo Capsules

A total of 1 patient in each cohort will receive Placebo Capsules: Cohort 1 will receive a single placebo capsule Cohort 2 will receive three placebo capsules Cohort 3 will receive ten placebo capsules (seven days apart) Cohort 4 will receive a single placebo capsule QD for 8 days Cohort 5 will receive three placebo capsules QD for 8 days Cohort 6 will receive ten placebo capsules QD for 8 days

Drug: Placebo Capsules

Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.

Outcome Measures

Primary Outcome Measures

Recording of adverse events [Screening through Day 28 follow-up]
Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the event.

Secondary Outcome Measures

Safety Laboratory Measurements [Screening through Day 15 (Part A&B)/Day 22 (Part C) visit]
Blood samples will be drawn and analyzed for: chemistry, hematology, lipids and coagulation.
Electrocardiogram [Screening through Day 15 (Part A&B)/Day 22 (Part C) visit]
Electrocardiograms will be captured and analyzed for changes throughout the duration of the study.
Vital Signs [Screening through Day 15 (Part A&B)/Day 22 (Part C) visit]
Vital signs (pulse, resting blood pressure, temperature and respirations) will be recorded and analyzed for changes throughout the duration of the study.
Physical Examination [Screening through Day 15 (Part A&B)/Day 22 (Part C) visit]
Physical examinations will be conducted to assess changes in subject health throughout the duration of the study.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Age 18 to 60 years old, inclusive
In good health as determined by the Investigator based on subject's medical history, ECG and physical examination at Baseline and safety laboratory tests (chemistry, hematology, coagulation and urinalysis) at Screening
Normal blood pressure of 130/85 mmHg or lower
Ability to provide written, informed consent prior to initiation of any study-related procedures, and ability, in the opinion of the Investigator, to comply with all the requirements of the study

Exclusion Criteria:

Women of childbearing potential, or men whose sexual partner(s) is a woman of childbearing potential who:

Are or intend to become pregnant (including use of fertility drugs) during the study
Are nursing
Are not using an acceptable, highly effective method of contraception until all follow-up procedures are complete. (Acceptable, highly effective forms of contraception are defined as: oral contraception, intrauterine device, systemic [injectable or patch] contraception, double barrier methods, naturally or surgically sterile, strict abstinence or partner has been sterilized. If hormonal-based birth control is being used, subject or subject's sexual partner(s) must be on a stable-dose for ≥ 3 months prior to the Baseline visit and maintained at the same dosing level throughout the study.)

Use of any drug treatment at the time of the study (with the exception of 81 mg aspirin and prescription oral or systemic contraceptives)
Taking any prescription medications (other than oral or systemic contraceptives) within 14 days prior to administration of investigational drug or taking any over-the-counter products (including natural food supplements, vitamins, garlic as a supplement) within 14 days prior to administration of investigational drug, except for topical products without systemic absorption
Use of NSAIDs or other prescription pain medication, more than once or twice a week, especially if taken for chronic or frequently recurring headache
Active infection within 3 days of the Baseline visit
History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or antibodies to Hepatitis C Virus (HCV)
Diagnosed with any form of internal cancer within the past 5 years
Any other medical conditions, diseases or prior surgeries that in the opinion of the Investigator would impair the subject from safely participating in the trial and/or completing any protocol requirements
History of anaphylactic reactions to any systemic or topical compounds
Have donated plasma (500 mL) within 7 days prior to drug administration
Have donated or lost whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows: 50 mL to 499 mL of whole blood within 30 days, or more than 499 mL of whole blood within 56 days prior to drug administration
Is a user of any nicotine products (including chewing tobacco, snuff and/or e-cigarettes)
Is not willing to restrict food or beverage including: alcohol, caffeine, poppy seeds, xanthine derivatives or xanthine-related compounds, energy drinks, natural health products, grapefruit juice, pomelo, Seville orange and marmalade use during the study as specified in Section 7.1.5
Is lactose intolerant
Is unable or unwilling to consume products containing bovine byproducts
Is unable to adhere to or understand the requirements of the protocol
If continuing on to Part B, subject is unable or unwilling to ingest the full study-provided high-fat breakfast within 30 minutes
Enrollment in any trial and/or use of any Investigational Drug or device within the immediate 30-day period prior to the Baseline visit
Enrollment in any study previously sponsored by Olatec Industries LLC, specifically Study OLT1177-01, Study OLT1177-02 or Study OLT1177-03